Sanofi’s Beyfortus Recommended for all Infants

Following the news of FDA-approval of Beyfortus (nirsevimab-alip) in July, the ACIP has now recommended the use of Beyfortus for all infants. Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

·     Neonates and infants born during or entering their first RSV season.

·     Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

In addition to the recommendation, the CDC has voted to include Beyfortus in the Vaccines for Children (VFC) program. See the ACIP recommendation.

How and When to Order Beyfortus

As of August 14th, 2023, Beyfortus orders can be placed directly via vaccineshop.com as a reservation for future shipments.

Beyfortus doses will begin to ship in early to mid-September 2023. Beginning in mid-September 2023, Beyfortus doses will be available as “order now, ship now”, similar to Sanofi pediatric vaccines.

PAA members linked to our Sanofi agreement* can now place orders and receive contract pricing.

Questions? Email Info@PAA.com.